Michael R. Mcdonnell - Sep 1, 2023 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
EVP, Chief Financial Officer
Signature
/s/ Wendell Taylor, attorney-in-fact for Michael R. McDonnell
Stock symbol
BIIB
Transactions as of
Sep 1, 2023
Transactions value $
-$722,428
Form type
4
Date filed
9/6/2023, 06:08 PM
Previous filing
May 22, 2023
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +2.68K +26.43% $0.00 12.8K Sep 1, 2023 Direct
transaction BIIB Common Stock Tax liability -$367K -1.37K -10.69% $267.17 11.5K Sep 1, 2023 Direct
transaction BIIB Common Stock Options Exercise $0 +2.6K +22.72% $0.00 14.1K Sep 1, 2023 Direct
transaction BIIB Common Stock Tax liability -$356K -1.33K -9.47% $267.17 12.7K Sep 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -2.68K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.68K $0.00 Direct F1
transaction BIIB Restricted Stock Unit Options Exercise $0 -2.6K -48.51% $0.00 2.76K Sep 1, 2023 Common Stock 2.6K $0.00 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -2.76K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.76K $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vested in three (3) equal annual installments commencing one year after the grant date of 09/01/2020.
F2 The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]).
F3 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.